{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-000603","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2022-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.151733+00:00","generated_at":"2026-06-27T21:23:03.277086+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acumen Pharmaceuticals amends executive employment agreements with new base salaries and severance terms","bullets":["CEO O'Connell: $551,200 base salary; 55% bonus target; 12-month non-CIC severance, 18-month CIC severance.","CFO Zuga: $415,300 base; 40% bonus target; 9-month non-CIC severance, 12-month CIC severance with 1.0x bonus lump sum.","CMO Siemers ($342,000 base) and COO Barton ($299,040 base) receive same severance structure as CFO.","CIC severance includes full acceleration of time-based equity awards in addition to cash severance and COBRA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-000603","json":"https://secwatch.observer/filing/0001193125-22-000603.json","markdown":"https://secwatch.observer/filing/0001193125-22-000603.md","text":"https://secwatch.observer/filing/0001193125-22-000603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522000603/0001193125-22-000603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522000603/d245848d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T21:23:03.277086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}